This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Annexin Pharmaceuticals Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Annexin Pharmaceuticals's earnings have been declining at an average annual rate of -8.6%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually.
Belangrijke informatie
-8.6%
Groei van de winst
40.2%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 30.5% |
Inkomstengroei | n/a |
Rendement op eigen vermogen | -731.5% |
Nettomarge | n/a |
Laatste winstupdate | 31 Mar 2024 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Opbrengsten en kosten
Hoe Annexin Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
31 Mar 24 | 0 | -46 | 9 | 38 |
31 Dec 23 | 0 | -44 | 8 | 36 |
30 Sep 23 | 0 | -40 | 13 | 26 |
30 Jun 23 | 0 | -38 | 12 | 26 |
31 Mar 23 | 0 | -41 | 11 | 30 |
31 Dec 22 | 0 | -41 | 12 | 28 |
30 Sep 22 | 0 | -47 | 8 | 37 |
30 Jun 22 | 0 | -45 | 9 | 35 |
31 Mar 22 | 0 | -43 | 11 | 32 |
31 Dec 21 | 0 | -52 | 11 | 42 |
30 Sep 21 | 0 | -53 | 10 | 45 |
30 Jun 21 | 0 | -53 | 11 | 44 |
31 Mar 21 | 0 | -55 | 11 | 46 |
31 Dec 20 | 0 | -44 | 11 | 34 |
30 Sep 20 | 0 | -38 | 10 | 28 |
30 Jun 20 | 0 | -36 | 10 | 27 |
31 Mar 20 | 0 | -31 | 8 | 23 |
31 Dec 19 | 0 | -28 | 8 | 21 |
30 Sep 19 | 0 | -25 | 8 | 17 |
30 Jun 19 | 0 | -24 | 7 | 16 |
31 Mar 19 | 0 | -25 | 8 | 17 |
31 Dec 18 | 0 | -29 | 8 | 20 |
30 Sep 18 | 0 | -31 | 8 | 23 |
30 Jun 18 | 0 | -30 | 8 | 22 |
31 Mar 18 | 0 | -32 | 8 | 25 |
31 Dec 17 | 0 | -31 | 7 | 24 |
30 Sep 17 | 0 | -25 | 6 | 20 |
30 Jun 17 | 0 | -26 | 4 | 22 |
31 Mar 17 | 0 | -17 | 3 | 15 |
31 Dec 16 | 0 | -10 | 1 | 9 |
31 Dec 15 | 0 | -5 | 6 | 0 |
Kwaliteitswinsten: ANNX BTA is currently unprofitable.
Groeiende winstmarge: ANNX BTA is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ANNX BTA is unprofitable, and losses have increased over the past 5 years at a rate of 8.6% per year.
Versnelling van de groei: Unable to compare ANNX BTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: ANNX BTA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.2%).
Rendement op eigen vermogen
Hoge ROE: ANNX BTA has a negative Return on Equity (-731.47%), as it is currently unprofitable.